Results 131 to 140 of about 160,542 (279)

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle‐Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab‐Gemcitabine‐Cisplatin Versus Gemcitabine‐Cisplatin: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

International Journal of Cancer, EarlyView.
Optimizing neoadjuvant therapy for muscle‐invasive bladder cancer patients who are eligible for cisplatin remains difficult, owing particularly to high toxicity and recurrence rates. This meta‐analysis compared dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) against durvalumab plus gemcitabine‐cisplatin (D‐GC) and GC alone ...
Maurin Helen Mangold, Gloria Baumann, Victoria Luise Simone Wieland, Nicolas Carl, Luisa Vivienne Renner, Alexander Studier‐Fischer, Hanna Menold, Stefanie Zschäbitz, Frederik Wessels, Niklas Westhoff, Maurice Stephan Michel, Karl‐Friedrich Kowalewski, Caelán Max Haney‐Aubert   +12 more
wiley   +1 more source

Pembrolizumab-induced duodenitis mimicking celiac disease

Pembrolizumab is a programmed cell death-1 (PD-1) inhibitor frequently used as primary immunotherapy in many cancers, including melanoma, lung, renal cell, cervical, urothelial, and gastric cancers. Given its immune-checkpoint inhibition and upregulation
Ehrenpreis, Eli D, Gonzalez, Miguel, Asado, Nahren, Lafazanos, Yannis, David, Robin   +4 more
core   +1 more source

Pembrolizumab in endometrial cancer: Where we stand now

, 2021
Recently, immunotherapy has shown promising results in solid tumors. To the best of our knowledge, this is the first systematic review of published literature synthesizing all the available data and evaluating both the efficacy and safety of ...
Georgakopoulou, Vasiliki E., Gavriatopoulou, Maria, Aravantinou-Fatorou, Aikaterini, Fiste, Oraianthi, Flora, Michael, Liontos, Dimopoulos, Meletios-Athanasios, Andrikopoulou, Angeliki, Zagouri   +9 more
core  

A case of severe visual loss related to treatment with pembrolizumab for metastatic renal pelvic cancer

IJU Case Reports
Introduction Pembrolizumab is the standard therapy for urothelial carcinoma treatment; however, adverse events have been noted. Here, we report a rare case of vision loss as an immune‐related adverse event of pembrolizumab therapy in a patient with ...
Naoki Inoue, Mihoko Iitzuka, Hiroki Tanaka, Yudai Ishikawa, Naoko Kawamura, Tetsuo Okuno   +5 more
doaj   +1 more source

The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta‐Analysis

International Journal of Cancer, EarlyView.
Currently, there are at least 30 ongoing clinical trials in the enrollment phase to evaluate adding concurrent ICIs to the PACIFIC regimen for a variety of solid tumors. Considering the lack of head‐to‐head comparative studies, this meta‐analysis aims to investigate the differences in efficacy between adding and not adding concurrent ICIs to CRT ...
Xu Tong, Zhenting Liu, Xiaoxiang Zhou, Nan Bi, Yibo Gao   +4 more
wiley   +1 more source

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

International Journal of Cancer, EarlyView.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel, Theresa Lowinus, Patrick Metzger, Rebecca Czurda, Vincent Schipperges, Ulrike Paul, Alessandra Rünger, Julian Kött, Isabel Heidrich, Saskia Lehr, Julia Kühn, Heiko Becker, Cornelius Miething, Martin Werner, Silke Laßmann, Justus Duyster, Tilman Brummer, Ronald Simon, Winfried Alsdorf, Maximilian Christopeit, Carsten Bokemeyer, Kilian Eyerich, Stefan W. Schneider, David Rafei, Melanie Börries, Frank Meiss, Christoffer Gebhardt   +26 more
wiley   +1 more source

Pembrolizumab for the Treatment of Locally Advanced Cutaneous Squamous Cell Carcinoma: Patient Selection and Special Considerations

Matthew Stewart,1 Jessica L Geiger2 1Department of Internal Medicine, Primary Care Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; 2Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation ...
Stewart M, Geiger JL
core  

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, EarlyView.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma

, 2018
Pembrolizumab is a monoclonal antibody directed against PD-1 that is US FDA approved for treatment of advanced PD-L1 positive gastric and gastroesophageal junction adenocarcinoma in patients who have progressed on at least two prior lines of ...
Smita S Joshi, Daniel V Catenacci, Steven B Maron   +2 more
core   +1 more source

The T‐Cell Response Mechanism in Human Papillomavirus‐Associated Cervical Cancer and New Strategies for Immunotherapy

iNew Medicine, EarlyView.
ABSTRACT Human papillomavirus (HPV) is a double‐stranded DNA virus that infects human skin and mucosal tissues exclusively. The German scientist Harald zur Hausen was awarded the 2008 Nobel Prize in Physiology or Medicine for his discovery of the link between HPV infection and cervical cancer.
Fang Zhu, Farah Nazir, Ying Zhou, Yuhua Shang, Hongliang He, Tengchuan Jin   +5 more
wiley   +1 more source